Enhanced Diagnosis of Respiratory Diseases Strengthens Growth of U.S. and China Asthma and COPD Drugs Market
The U.S. and China asthma and COPD drugs market is poised to undergo steady development from 2016 to 2024. This market is predicted to experience a moderate development in the first half of the forecast horizon in both the U.S. and China, majorly owing to price erosion and top drug brands’ patent expiry. However, post 2020, the growth of the market in the U.S. and China will be on boom due to the increasing penetration of novel drugs.
Transparency Market Research (TMR), a market intelligence company, highlights the leading drugs in the market. It also throws light on the forces boosting and impeding the development of this market in both the U.S. and China.
Which forces will drive the development of the U.S and China asthma and COPD drugs market?
The increasing awareness amongst individuals will drive the development of the asthma and COPD drugs market in the U.S. and China. In addition, the enhanced diagnosis of respiratory diseases in these nations will bolster the growth of this market. Furthermore, the growing pool of patients in both the U.S and China, particularly in the last decade, will positively impact the development of this market. Statistics depict that the occurrence of asthma in China is between 1% and 2%, however it over 10% in other cities. The prevalence of asthma in Shanghai recorded a rise of more than 190% in the last decade. In addition, the cases of asthma have also seen a rise in the U.S. in the past. As per the Centers for Disease Control and Prevention (CDC), approximately one in 12 individuals within the U.S has asthma, which comes out to be 25 mn individuals in the entire nation.
Furthermore, the increasing employment of biologics in asthma, a new treatment method, will also bode well for the growth of this market in the U.S and China. However, frequent product recalls and blockbuster brands’ patent expiry may emerge as roadblocks in the development of this market in the U.S and China.
Which drug class excelled in 2015 and why?
In terms of drug class, the segment of combination drugs held a top share of more than 54% in the asthma and COPD drugs market in the U.S. and China in 2015. This drug class is predicted to experience development all through the forecast horizon due to their increasing preference and popularity amongst patients residing in the U.S. and China. In addition, the introduction of triple combination therapies by companies such as Circassia, GSK, and Chiesi Pharmaceuticals will also bolster the development of this segment. On the other hand, monoclonal antibodies will also experience significant demand in the market in forthcoming years due to the introduction of new improved products in this segment in the coming years.
Which nation will experience the most exponential growth in asthma and COPD drugs?
Amongst the U.S. and China, the U.S has emerged as the market leader and represented a share of 81.4% by 2016. It is predicted to maintain its dominance all through 2024. However, on the basis of market size, the growth of this market in the U.S will fall initially owing to less sales because of off-patent blockbuster drugs’ decreasing revenue. Nonetheless, launch of new products will drive the development of the asthma and COPD drugs market in China from 2021 onwards.
On the other hand, though China holds a meagre share in the market, still this nation is said to be the most lucrative market. It is poised to exhibit a remarkable 10.0% CAGR between 2016 and 2024. This is owing to the increasing medical unmet needs and the skyrocketing count of individuals having asthma.